Publications by authors named "N Karminsky"
Purpose: BRCA1/2 founder pathogenic variants (PVs) occur in various populations, but data on the mutational spectrum in Africans are limited. We examined BRCA1/2 PVs in breast cancer patients of Ethiopian Jewish (EJ) origin.
Methods: We retrospectively analyzed BRCA1/2 test results and clinical features of EJ breast cancer patients from seven medical institutions.
Article Synopsis
- The 21-gene Recurrence Score® (RS) assay helps predict outcomes in ER+ early-stage breast cancer, but there’s a lack of real-life data for patients with high RS scores (≥11).
- This retrospective study analyzed 1801 ER+ HER2-negative breast cancer patients who underwent RS testing between 2006 and 2010, focusing on their treatment outcomes over an average follow-up of 6.2 years.
- Results indicated that patients with lower RS scores (RS < 18) had very low rates of distant recurrence and breast cancer death, supporting the effectiveness of endocrine therapy alone, even for those with RS scores of 11-25 who did not receive chemotherapy.
Background: Postoperative chemoradiation as per Intergroup-0116 trial ("Macdonald regimen") is considered standard for completely resected high risk gastric cancer. However, many concerns remain with regards to the toxicity of this regimen. To evaluate the safety and tolerability of this regimen in a routine clinical practice setting, we analyzed our experience with its use.
View Article and Find Full Text PDFMore than two-thirds of patients with gastric cancer present with metastatic disease and their curative options are limited. This phase II study assessed the efficacy and tolerability of cisplatin, epirubicin, tegafur-uracil (UFT) and leucovorin in patients with metastatic gastric cancer (MGC). Thirty-nine patients with previously untreated metastatic or unresectable gastric cancer received intravenous cisplatin 60 mg/m2 and epirubicin 50 mg/m2 on day 1 of a 28-day cycle; UFT 300 mg/m2 was administered with oral leucovorin 30 mg/day in divided doses on days 1-22, followed by a 7-day rest.
View Article and Find Full Text PDFThe Israeli Society for Clinical Oncology and Radiotherapy appointed experts in breast cancer therapy to assess the Society's policy regarding hormone replacement therapy (HRT) in breast cancer survivors with menopausal symptoms. The first policy letter was published in November 2002, and referred to available literature at that time which included retrospective data alone. The professional literature suggested no increased risk in breast cancer recurrence or cancer specific mortality, and no effect on overall survival with the use of HRT for a limited period (up to 3 years).
View Article and Find Full Text PDF